Skip to main content
Log in

Aripiprazole

A Review of its Use in Schizophrenia and Schizoaffective Disorder

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Aripiprazole, a quinolinone derivative, is an atypical antipsychotic drug indicated for the treatment of adult patients with schizophrenia.

Aripiprazole 10 or 15mg once daily is effective and well tolerated in patients with schizophrenia or schizoaffective disorder. Although aripiprazole has only been directly compared with haloperidol and olanzapine in treatment-responsive patients to date, current data generally indicate that aripiprazole has a beneficial profile in terms of a low potential for bodyweight gain. Dosage titration is not necessary and the drug is effective in the first few weeks of treatment. Head-to-head comparative trials with atypical antipsychotic agents are required, as are long-term (≥1 year) studies, to fully define the position of aripiprazole in relation to other antipsychotic drugs. Aripiprazole is a valuable new therapeutic option in the management of patients with schizophrenia.

Pharmacological Properties

Aripiprazole is a quinolinone derivative with a high affinity for dopamine D2 and D3 receptors, and serotonin 5-HT1a, 5-HT2A and 5-HT2B receptors. The mechanism of action of aripiprazole is not yet known, but evidence suggests that its efficacy in the treatment of the positive and negative symptoms of schizophrenia and its lower propensity for extrapyramidal symptoms (EPS) may be attributable to aripiprazole’s partial agonist activity at dopamine D2 receptors. At serotonin 5-HT1a receptors, in vitro studies have shown that aripiprazole acts as a partial agonist whereas at serotonin 5-HT2A receptors aripiprazole is an antagonist. The main active metabolite, dehydro-aripiprazole, has affinity for dopamine D2 receptors and thus has some pharmacological activity similar to that of the parent compound.

Aripiprazole is rapidly absorbed after oral administration. The mean time to peak plasma concentration is 3 hours following multiple-dose administration of aripiprazole 10 or 15mg and the absolute oral bioavailability of the drug is 87%. Steady-state plasma drug concentrations are achieved by 14 days; however, the drug appears to accumulate over this period, since mean peak plasma concentration and mean area under the plasma concentration-time curve values of aripiprazole 10 or 15 mg/day are 4-fold greater on day 14 than on day 1. This accumulation may be expected, since the mean elimination half-life of a single dose of aripiprazole is about 75 hours.

Aripiprazole has extensive extravascular distribution and more than 99% of aripiprazole and dehydro-aripiprazole (the main active metabolite of aripiprazole) is bound to plasma protein.

Elimination of the drug is primarily hepatic; the cytochrome P450 (CYP) 3A4 and CYP2D6 enzyme systems transform aripiprazole to dehydro-aripiprazole, with the latter enzyme system subject to genetic polymorphism. Thus, dosage adjustment of aripiprazole is necessary when it is coadministered with CYP3A4 and CYP2D6 inhibitors (since aripiprazole concentration is increased) and with inducers of CYP3A4 (since aripiprazole concentration is decreased).

Therapeutic Efficacy

The efficacy of aripiprazole has been demonstrated in patients with schizophrenia or schizoaffective disorder. In general, significant reductions from baseline in mean Positive and Negative Syndrome Scale total, positive and negative symptom scores, and Clinical Global Impression Severity of Illness scores were observed in patients with acute relapse of chronic schizophrenia or schizoaffective disorder receiving recommended (10 or 15 mg/day) or higher-than-recommended (20 or 30 mg/day) dosages of aripiprazole versus those receiving placebo in three well controlled, short-term trials. No additional therapeutic benefit was observed at the higher-than-recommended dosages. The drug is effective as early as the first or second week of treatment.

The efficacy of aripiprazole was maintained for up to 52 weeks. The drug was significantly more effective than placebo in preventing relapse in patients with stable chronic schizophrenia in a 26-week, randomised trial. In a 52-week trial in patients with acute relapse of schizophrenia, the percentage of responders maintaining a response at study end was 77% of aripiprazole versus 73% of haloperidol recipients.

Aripiprazole may improve cognitive function. In a nonblind, 26-week trial, patients with chronic schizophrenia receiving aripiprazole 30 mg/day experienced similar (general cognitive function) or better (verbal learning) changes from baseline in the neurocognitive parameters evaluated compared with recipients of olanzapine 10–15 mg/day.

Tolerability

Aripiprazole 10–30 mg/day was generally well tolerated. The tolerability profile of aripiprazole was broadly similar to that observed with placebo in a meta-analysis of short-term trials in patients with acute relapse of schizophrenia or schizoaffective disorder and in a 26-week trial in patients with chronic stable schizophrenia. The most frequent treatment-emergent adverse events included insomnia and anxiety, and additionally, headache and agitation (in short-term trials) or akathisia and psychosis (in a 52-week trial).

In general, the drug was associated with a placebo-level incidence of EPS and EPS-related adverse events. Significantly fewer aripiprazole recipients experienced EPS-related adverse events than haloperidol recipients in a 52-week trial. Changes in severity of EPS were minimal and usually no different from those observed with placebo. Moreover, there was less severe EPS in the aripiprazole group than the haloperidol group in a long-term trial. Treatment-emergent tardive dyskinesia was reported in only 0.2% of patients receiving aripiprazole (short-term trials), an incidence similar to that seen in placebo recipients (0.2%).

Aripiprazole has a low propensity to cause clinically significant bodyweight gain, hyperprolactinaemia or corrected QT interval prolongation in patients with schizophrenia or schizoaffective disorder. In addition, there were no clinically relevant differences in mean changes from baseline in measures of diabetes and dyslipidaemia between the aripiprazole or placebo groups in a 26-week, placebo-controlled trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Fig. 2
Table IV

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. World Health Organization. Schizophrenia [online]. Available from URL: http://www.who.int/mental_health/schizophrenia/ [Accessed 2004 Jan 15]

  2. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry 1999; 60 Suppl. 3: 3–7

    Google Scholar 

  3. McElroy SL, Keck Jr PE, Strakowski SM. An overview of the treatment of schizoaffective disorder. J Clin Psychiatry 1999; 60 Suppl. 5: 16–21

    Google Scholar 

  4. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Second edition [online]. Available from URL: http://www.psych.org [Accessed 2004 Mar 25]

  5. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical Guideline1. London: National Institute for Clinical Excellence, 2002 Dec

  6. Baethge C. Long-term treatment of schizoaffective disorder: review and recommendations. Pharmacopsychiatry 2003; 36(2): 45–56

    Article  PubMed  CAS  Google Scholar 

  7. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 28 Suppl. 1: 9–26

    Article  Google Scholar 

  8. Citrome L, Volavka J. Atypical antipsychotics: revolutionary or incremental advance? Expert Review of Neurotherapeutics 2002; 2(1): 69–88

    Article  PubMed  CAS  Google Scholar 

  9. Keltner NL, Johnson V. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect Psychiatr Care 2002 Oct–Dec; 38(4): 157–9

    Google Scholar 

  10. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002; 16(11): 779–86; discussion 787-8

    Article  PubMed  CAS  Google Scholar 

  11. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2 (1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995 Jul; 274(1): 329–36

    PubMed  CAS  Google Scholar 

  12. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003 Aug; 28(8): 1400–11

    Article  PubMed  CAS  Google Scholar 

  13. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002 Jul; 302(1): 381–9

    Article  PubMed  CAS  Google Scholar 

  14. Inoue T, Domae M, Yamada K, et al. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2 (1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996 Apr; 277(1): 137–43

    PubMed  CAS  Google Scholar 

  15. McQuade R, Burris KD, Jordan S, et al. Aripiprazole: a dopamine-serotonin system stabilizer [abstract no. P.3.W.080]. Int J Neuropsychopharmacol 2002 Jun; 5 Suppl. 1: S176. Plus poster presented at the 23rd Collegium Internationale Neuro-Psychopharmacologicum Congress; 2002 Jun 23–27; Montreal

  16. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999 Jun; 20(6): 612–27

    Article  PubMed  CAS  Google Scholar 

  17. Yocca FD, Kikuchi T. The next generation antipsychotic aripiprazole inhibits the conditioned avoidance response and apomorphine stereotypy in rats [abstract no. 347]. Biol Psychiatry 2003 Apr 15; 53 Suppl.: 122S–3S

    Google Scholar 

  18. Fujikawa M, Nagashima M, Inoue T, et al. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav 1996 Apr; 53(4): 903–9

    Article  PubMed  CAS  Google Scholar 

  19. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997; 321(1): 105–11

    Article  PubMed  Google Scholar 

  20. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1a receptor. Eur J Pharmacol 2002 Apr 26; 441(3): 137–40

    Article  PubMed  CAS  Google Scholar 

  21. Mallikaarjan S, Salazar DE, Bramer SL. Time of dosing and food effects on aripiprazole pharmacokinetics [abstract no. NR564 plus poster]. American Psychiatric Association 2003 Annual Meeting: New Research Abstracts; 2003 May 17–22; San Francisco, 211

  22. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002 Aug; 27(2): 248–59

    Article  PubMed  CAS  Google Scholar 

  23. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. Abilify™ (aripiprazole) tablets prescribing information [online]. Available from URL: http://www.abilify.com [Accessed 2004 Apr 15]

  24. Sugiyama A, Satoh Y, Hashimoto K. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol 2001 Jun 1; 173(2): 120–8

    Article  PubMed  CAS  Google Scholar 

  25. Gründer G, Carlsson A, Wong DF. Mechanism of new anti-psychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003 Oct; 60(10): 974–7

    Article  PubMed  Google Scholar 

  26. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004; 18(4): 251–67

    Article  PubMed  CAS  Google Scholar 

  27. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001 Dec; 62(12): 923–4

    Article  PubMed  CAS  Google Scholar 

  28. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: ‘Goldilocks’ actions at dopamine receptors. J Clin Psychiatry 2001 Nov; 62(11): 841–2

    Article  PubMed  CAS  Google Scholar 

  29. Amano T, Matsubayashi H, Momiyama T, et al. Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry 1995 Jan; 19(1): 105–16

    Article  PubMed  CAS  Google Scholar 

  30. Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology (Berl) 1999 Sep; 146(2): 139–43

    Article  CAS  Google Scholar 

  31. Momiyama T, Amano T, Todo N, et al. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol 1996 Aug 22; 310(1): 1–8

    Article  PubMed  CAS  Google Scholar 

  32. Nakai S, Hirose T, Uwahodo Y, et al. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol 2003 Jul 4; 472(1–2): 89–97

    Article  PubMed  CAS  Google Scholar 

  33. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44(2): 179–87

    Article  PubMed  CAS  Google Scholar 

  34. Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers [abstract no. P.4.E.035]. Int J Neuropsychopharmacol 2002 Jun; 5 Suppl. 1: (S187) Plus poster presented at the 23rd Collegium Internationale Neuro-Psychopharmacologicum Congress; 2002 Jun 23–27; Montreal

  35. Bramer SL, Shoaf S, Salazar DE, et al. Renal and hepatic impairment of the pharmacokinetics of aripiprazole [abstract no. NR548 plus poster]. American Psychiatric Association 2003 Annual Meeting: New Research Abstracts; 2003 May 17–22; San Francisco, 205

  36. Mallikaarjun S, Ali MW, Salazar DE, et al. The effects of age and gender on the pharmacokinetics of aripiprazole [abstract no. TPII-90]. Clin Pharmacol Ther 2002 Feb; 71(2): 66

    Google Scholar 

  37. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stablized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003 Sep; 64(9): 1048–56

    Article  PubMed  CAS  Google Scholar 

  38. Comblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis [abstract no. P.4.E.027]. Int J Neuropsychopharmacol 2002 Jun; 5 Suppl. 1: 185–186. Plus poster presented at the 23rd Collegium Internationale Neuro-Psychopharmacologicum Congress; 2002 Jun 23–27; Montreal

    Google Scholar 

  39. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003 Nov 11; 6: 325–37

    CAS  Google Scholar 

  40. US FDA Center for Drag Evaluation and Research. Medical Review(s) Part 1–4: review and evaluation of clinical data NDA #21-436 [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm [Accessed 2003 Sep 23]

  41. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60(7): 681–90

    Article  PubMed  CAS  Google Scholar 

  42. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002 Sep; 63(9): 763–71

    Article  PubMed  CAS  Google Scholar 

  43. Tandon R, Stock EG, Riera L, et al. A naturalistic trial with aripiprazole in a general psychiatric setting [abstract no. NR603 plus poster]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York [abstracts-on-disk]

  44. Lieberman J, Carson WH, Saha AR, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia [abstract no. P.4.E.031]. Int J Neuropsychopharmacol 2002 Jun; 5 Suppl. 1:186. Plus poster presented at the 23rd Collegium Internationale Neuro-Psychopharmacologicum Congress; 2002 Jun 23–27; Montreal

  45. Carson Jr WH, Archibald DG, Manos G, et al. Short-term efficacy of aripiprazole on depression and anxiety in schizophrenia [abstract no. NR549 plus poster]. American Psychiatric Association 2003 Annual Meeting: New Research Abstracts; 2003 May 17–22; San Francisco, 205–6

  46. Kujawa MJ, Stringfellow J, Hardy S, et al. The efficacy of aripiprazole in patients with schizoaffective disorder [abstract no. NR536 plus poster]. American Psychiatric Association 2003 Annual Meeting: New Research Abstracts; 2003 May 17–22; San Francisco, 200–1

  47. Dillenschneider A, Marcus R, Kostic D, et al. Effects of aripiprazole on the excitement/hostility symptoms of schizophrenia [abstract no. P01.424]. Int J Neuropsychopharmacol 2004 Jun; 7 Suppl. 1: S243. Plus poster presented at 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 Jun 20–24; Paris

    Google Scholar 

  48. Marder S, Archibald D, Manos G, et al. Long-term effects of aripiprazole therapy on the negative symptoms of schizophrenia [abstract no. P01.422]. Int J Neuropsychopharmacol 2004 Jun; 7 Suppl. 1: S243. Plus poster presented at 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 Jun 20–24; Paris

    Google Scholar 

  49. Octavio I, Stock E, Archibald D, et al. Long-term effects of aripiprazole on affective symptoms of schizophrenia [abstract no. P02.430]. Int J Neuropsychopharmacol 2004 Jun; 7 Suppl. 1: S417. Plus poster presented at the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 Jun 20–24; Paris

  50. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  51. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003 Apr; 166(4): 391–9

    CAS  Google Scholar 

  52. Brown D, McEvoy J, Saha A, et al. Aripiprazole in patients with first episode schizophrenia [abstract]. International Congress on Schizophrenia Research in conjunction with the 6th Biennial Mt. Sinai Conference on Cognition in Schizophrenia; 2003 Mar 29–Apr 2; Colorado Springs

  53. Toru M, Miura S, Kudo Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients [abstract no. S-16-9]. Neuropsychopharmacology 1994 May; 10 Suppl. 3 Pt 1: 122S

    Google Scholar 

  54. Toru M, Miura S. Late phase II study of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients [abstract no. S-2-5]. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 18

    Article  Google Scholar 

  55. Daniel DG, Saha AR, Ingenito G, et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result [abstract no. P.01.242]. Int J Neuropsychopharmacol 2000 Jul; 3 Suppl. 1: S157

    Google Scholar 

  56. Gismondi R, Meltzer H, Kujawa M, et al. Aripiprazole versus perphenazine in treatment-resistant schizophrenia [abstract no. P02.427]. Int J Neuropsychopharmacol 2004 Jun; 7 Suppl. 1: S417

    Google Scholar 

  57. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261–76

    Article  PubMed  CAS  Google Scholar 

  58. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003 Jun 1; 61(2–3): 123–36

    Article  PubMed  Google Scholar 

  59. Weiden P, Waldeck R, Tafesse E, et al. Projected risk of coronary heart disease in schizophrenia: a comparison between aripiprazole and olanzapine [abstract no. 729-P]. Diabetes 2003; 52 Suppl. 1: A170

    Google Scholar 

  60. Stock E, Saha A, Brunell R, et al. Meta-analysis of cardiac safety with aripiprazole [abstract no. P.4.E.029]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1:186. Plus poster presented at the 23rd Collegium Internationale Neuro-Psychopharmacologicum Congress; 2002 Jun 23–27; Montreal

  61. Jody D, Saha AR, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole [abstract no. P.4.E.030]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1:186. Plus poster presented at the 23rd Collegium Internationale Neuro-Psychopharmacologicum Congress; 2002 Jun 23–27; Montreal

  62. Kujawa M, McQuade R, Jody D, et al. Long-term weight effects of aripiprazole vs olanzapine in a 26-week, double-blind study. Int J Neuropsychopharmacol 2004 Jun; 7 Suppl. 1: S234. Plus poster presented at the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 Jun 20–24; Paris

  63. Bristol-Myers Squibb. Abilify® (aripiprazole) Approved for marketing in Europe for the treatment of schizophrenia [media release]. 2004

  64. Bristol-Myers Squibb, Otsuka Pharmaceutical Co. Ltd OPCL. FDA approves Abilify (TM) (Aripiprazole) supplemental new drug application (sNDA) for maintaining stability in patients with schizophrenia [online]. Available from URL: http://www.bms.com [Accessed 2003 Sep 11]

  65. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000; 22(3): 195–214

    Article  PubMed  CAS  Google Scholar 

  66. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27(2): 596–601

    Article  Google Scholar 

  67. US FDA. Warning about hyperglycemia and atypical antispychotic drugs. FDA patient safety news: show #28, June 2004 [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id=229 [Accessed 2004 Jun 16]

  68. Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64 Suppl. 12: 5–19

    Google Scholar 

  69. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2004 Feb; 2: CD004578

    PubMed  Google Scholar 

  70. FDA MedWatch. 2004 Safety Alert: Abilify (aripiprazole) [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2004/abilify.htm [Accessed 2004 Jun 16]

  71. Janssen Pharmaceutica Products LP. Risperdal® (Risperidone) prescribing information [online]. Available from URL: http://www.risperdal.com0 [Accessed 2004 Apr 5]

  72. Cheer SM, Wagstaff AJ. Quetiapine: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18(3): 173–99

    Article  PubMed  CAS  Google Scholar 

  73. Gunasekara NS, Spencer CM, Keating G.M.. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2002; 62(8): 1217–51

    Article  PubMed  CAS  Google Scholar 

  74. Janssen-Cilag. Haldol Tablets/Oral Solution™ (haloperidol). Summary of product characteristics [online]. Available from URL: http://www.janssen-cilag.co.uk/product/pdf/spc00034.pdf [Accessed 2004 Apr 8

  75. Ruppert A, Waldeck R, Cislo P, et al. An economic evaluation of aripiprazole versus olanzapine in a Swedish setting using outcomes of metabolic syndrome, projected diabetes and coronary heart disease [abstract no. PMH16]. Value Health 2003 Nov–Dec; 6(6): 694–5

    Article  Google Scholar 

  76. Heinen-Kammerer T, Motzkat K, Ruppert A, et al. Cost-effectiveness-analysis: long-term adverse drug reactions of schizophrenia therapy with aripiprazole versus olanzapine [abstract no. P02.426]. Int J Neuropsychopharmacol 2004 Jun; 7 Suppl. 1: S416. Plus poster presented at the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 Jun 20–24; Paris

  77. Winans E. Aripiprazole. Am J Health-Syst Pharm 2003 Dec; 60: 2437–45

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tracy Swainston Harrison.

Additional information

Various sections of the manuscript reviewed by: B.A. Cornblatt, Director, Recognition and Prevention Program, The Zucker Hillside Hospital, Lake Success, New York, USA; J.M. Davis, Psychiatric Institute, University of Illinois at Chicago, Chicago, Illinois, USA; S. Kasper, Department of General Psychiatry, Medical University of Vienna, Vienna, Austria; M. Lader, Institute of Psychiatry, King’s College London, London, United Kingdom; S.R. Marder, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA; T. Pigott, Department of Psychiatry, University of Florida, Gainesville, Florida, USA; D.M. Taylor, Pharmacy Department, Maudsley Hospital, London, United Kingdom; D.A. Wirshing, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.

Data Selection

Sources: Medical literature published in any language since 1980 on aripiprazole, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: Medline search terms were ‘aripiprazole’ or ‘OPC-14597’. EMBASE search terms were ‘aripiprazole’ or ‘OPC-14597’. AdisBase search terms were ‘aripiprazole’ or ‘OPC-14597’. Searches were last updated 30 June 2004.

Selection: Studies in patients with schizophrenia or schizoaffective disorder who received aripiprazole. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Aripiprazole, Abilify, Abilitat, OPC 14597, schizophrenia, schizoaffective disorder, maintenance phase, acute relapse, atypical antipsychotic, neuroleptic, dopamine system stabiliser, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, T.S., Perry, C.M. Aripiprazole. Drugs 64, 1715–1736 (2004). https://doi.org/10.2165/00003495-200464150-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464150-00010

Keywords

Navigation